ISRCTN14767579已完成未知
A 3-month Electronic Nicotine Delivery System (ENDS)-based intervention in a homeless context: efficacy, challenges and opportunities
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 23
研究概览
简要总结
2020 results in https://pubmed.ncbi.nlm.nih.gov/33046080/ (added 16/10/2020)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. >5 COppm
- •2. Active smoking status
- •3. Expressed intention to quit using ENDS-device
排除标准
- •1. Active pregnancy status
- •2. Exhibition of acute florid mental health or substance use-related issues
研究者
相似试验
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-HUovartis Pharma Service AG500
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-DEovartis Pharma Service AG500
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab 0.3 mg in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - NDEUCTR2005-005921-73-ITOVARTIS FARMA600
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIEUCTR2005-005921-73-PTovartis Pharma Service AG500
进行中（未招募）
1 期
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-NLovartis Pharma Service AG